APM
IMVT icon

Avidity Partners Management’s Immunovant IMVT Stock Holding History

Avidity Partners Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-99,000
Closed -$2.82M – 75
2024
Q3 		$2.82M Sell
99,000
-809,000
-89% -$23.9M 0.14% 71
2024
Q2 		$24M Buy
908,000
+403,000
+80% +$11.5M 1.02% 42
2024
Q1 		$16.3M Buy
505,000
+260,000
+106% +$9.49M 0.53% 56
2023
Q4 		$10.3M Sell
245,000
-928,662
-79% -$34.2M 0.38% 61
2023
Q3 		$45.1M Sell
1,173,662
-911,338
-44% -$20.6M 1.81% 18
2023
Q2 		$39.6M Buy
2,085,000
+1,042,000
+100% +$19.4M 1.38% 30
2023
Q1 		$16.2M Buy
+1,043,000
New +$18.1M 0.54% 58

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Avidity Partners Management's IMVT Position: Q4 2024 in Review

Avidity Partners Management sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 99,000 shares — an estimated $2.82M sold.

Avidity Partners Management first reported a position in IMVT in Q1 2023 and held it in 7 quarters. The position peaked at $45.1M in Q3 2023. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

  • Avidity Partners Management reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
  • Avidity Partners Management sold 99,000 Immunovant shares in Q4 2024, an estimated $2.82M.
  • Avidity Partners Management first reported a position in Immunovant in Q1 2023 and held it in 7 quarters.
  • Avidity Partners Management's Immunovant position peaked at $45.1M in Q3 2023.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.